Related Experiment Videos
CD40-CD40L interaction in Alzheimer's disease.
Jun Tan1, Terrence Town, Mike Mullan
1The Roskamp Institute, Department of Psychiatry, University of South Florida, 3515 East Fletcher Avenue, Tampa, Florida 33613, USA. jtan@hsc.usf.edu
Current Opinion in Pharmacology
|July 20, 2002
Summary
The CD40-CD40L interaction exacerbates Alzheimer's disease (AD) pathology by promoting microglial activation. Reducing this interaction may offer a therapeutic strategy for AD by mitigating neuroinflammation and Tau pathology.
Area of Science:
- Neuroscience
- Immunology
- Pathology
Background:
- The CD40 receptor-CD40 ligand (CD40-CD40L) interaction plays a role in Alzheimer's disease (AD) pathogenesis.
- This interaction synergizes with amyloid-beta to activate microglia, releasing neurotoxic substances.
- Microglial activation and neurotoxicity are key features of AD.
Purpose of the Study:
- To investigate the role of the CD40-CD40L system in AD pathogenesis.
- To determine if reducing CD40-CD40L interaction impacts AD-related pathology in a mouse model.
Main Methods:
- Utilized a transgenic mouse model of AD.
- Crossed AD mice with CD40L-deficient mice.
- Assessed microgliosis and Tau hyperphosphorylation as indicators of AD pathology.
Main Results:
- Mice lacking CD40L showed reduced gliosis compared to AD mice with CD40L.
- Complete absence of AD-like Tau hyperphosphorylation was observed in CD40L-deficient AD mice.
- CD40-CD40L interaction critically enhances microglial activation and neuronal stress in AD.
Conclusions:
- The CD40-CD40L system is a key enhancer of microglial activation in AD.
- Reduced CD40-CD40L interaction is associated with decreased microgliosis and Tau pathology.
- Targeting microgliosis via CD40-CD40L modulation may be a beneficial therapeutic approach for AD.